CTOs on the Move

General Healthcare Resources

www.ghresources.com

 
General Healthcare Resources is a Plymouth Meeting, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.ghresources.com
  • 2250 Hickory Rd Ste 240
    Plymouth Meeting, PA USA 19462
  • Phone: 800.879.4471

Executives

Name Title Contact Details

Similar Companies

Star Multi Care Services

Star Multi Care Services is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assisted Living at Spring Oak

Assisted Living at Spring Oak is a Lanoka Harbor, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Citizens Acting Together Can Help (CATCH)

Citizens Acting Together Can Help (CATCH) is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Claremont Partners

Claremont Partners is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.